Economic endpoints in clinical trials.
Healthcare decision makers are increasingly requesting information on the cost and cost-effectiveness of new medicines at the time of product launch. In order to provide this information, data on healthcare resource utilization and, in some cases, costs, may be collected in clinical trials. In this paper, we discuss some of the issues statisticians need to address when it is appropriate to include these economic endpoints in the trial. Several design issues are discussed, including the alternative types of and methods for collecting economic endpoint data, sample size and generalizability. Alternative approaches in the analysis of resource utilization, cost and cost-effectiveness are also presented. Finally, several of the analytic approaches are applied to actual data from a clinical trial.
Cook
John
J
Merck Research Laboratories, Blue Bell, PA 19422, USA. john_cook@merck.com
Drummond
Michael
M
Heyse
Joseph F
JF
D002986:Clinical Trials as Topic / Q000191:economics* / Q000706:statistics & numerical data; D003362:Cost-Benefit Analysis / Q000706:statistics & numerical data; D003625:Data Collection; D023381:Endpoint Determination / Q000191:economics* / Q000706:statistics & numerical data; D006801:Humans; D014481:United States